Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00636896 · ClinicalTrials.gov registry record · NA
Effects of Modafinil on Olanzapine Weight Gain
A NA study, sponsored by Neuropsychiatric Research Institute, Fargo, North Dakota.
- Completed
- Registry status
- NA
- Development phase
- 50
- Enrollment target
NCT00636896: Completed NA study, sponsored by Neuropsychiatric Research Institute, Fargo, North Dakota.
NCT00636896 is a NA study that has completed, run by Neuropsychiatric Research Institute, Fargo, North Dakota. The registered enrollment target is 50 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00636896, a NA study, has completed, sponsored by Neuropsychiatric Research Institute, Fargo, North Dakota.
- COMPLETED
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
Study Summary
This study is designed as a 3 week, randomized, double blind, placebo controlled, trial. Olanzapine and modafinil will be titrated to 10mg and 200mg respectively. Feeding lab assessments will be conducted at baseline and endpoint. Assessments of hunger/satiety, kilocalories consumed and weight will be obtained. Plasma ghrelin and PYY3-36 levels will be drawn at baseline and endpoint prior to breakfast and two hours post. Study hypothesis: The modafinil/olanzapine group will gain less weight than the olanzapine/placebo group over three weeks of drug intake.
Interventions
- DRUG Olanzapine plus modafinil
- DRUG Olanzapine plus placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2006-07 |
| Est. Completion | 2007-08 |
| Phase | NA |
What the finished NCT00636896 record still lists
NCT00636896 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which Olanzapine plus modafinil is the first listed.
NCT00636896 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00636896 about?
NCT00636896 is a clinical study titled "Effects of Modafinil on Olanzapine Weight Gain". This study is designed as a 3 week, randomized, double blind, placebo controlled, trial. Olanzapine and modafinil will be titrated to 10mg and 200mg respectively. Feeding lab assessments will be conducted at baseline and endpoint. Assessments of hunger/satiety, kilocalories consumed and weight will ...
What is the current status of trial NCT00636896?
This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2006-07. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00636896?
The interventions under investigation include: Olanzapine plus modafinil (DRUG), Olanzapine plus placebo (DRUG).
Who is sponsoring clinical trial NCT00636896?
This trial is sponsored by Neuropsychiatric Research Institute, Fargo, North Dakota, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00636896's enrollment target sits among peer trials
50 1279th of 2000 higher than 622 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia